UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING
AND/OR REGISTRATION UNDER SECTION 12(b)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number:001-36886001-36887
Allergan Funding SCS
(as issuer)
Allergan Capital S.à r.l.
Allergan Finance, LLC
Warner Chilcott Limited
(as guarantors)
NEW YORK STOCK EXCHANGE
(Exact name of Issuer as specified in its charter, and name of Exchange
where security is listed and/or registered)
The addresses and telephone numbers for each entity are listed in Annex A hereto
(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)
Floating rate notes due 2020 (and the guarantees related thereto)
0.500% notes due 2021 (and the guarantees related thereto)
1.500% notes due 2023 (and the guarantees related thereto)
1.250% notes due 2024 (and the guarantees related thereto)
2.625% notes due 2028 (and the guarantees related thereto)
2.125% notes due 2029 (and the guarantees related thereto)
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
☐ | 17 CFR240.12d2-2(a)(1) |
☐ | 17 CFR240.12d2-2(a)(2) |
☐ | 17 CFR240.12d2-2(a)(3) |
☐ | 17 CFR240.12d2-2(a)(4) |
☐ | Pursuant to 17 CFR240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1 |
☒ | Pursuant to 17 CFR240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR240.12d2-2(c) governing voluntary withdrawal of the class of securities from listing and registration on the Exchange. |
1 | Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR240.19d-1 as applicable. See General Instructions. |
Pursuant to the requirements of the Securities Exchange Act of 1934, each of Allergan Funding SCS, Allergan Capital S.à r.l., Allergan Finance, LLC and Warner Chilcott Limited certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
Allergan Funding SCS | ||||
DATE: May 11, 2020 | By: | /s/ Pradipto Bagchi | ||
Name: Pradipto Bagchi | ||||
Title: Class A Manager | ||||
DATE: May 11, 2020 | By: | /s/ Severine Lucie Canova | ||
Name: Severine Lucie Canova | ||||
Title: Class B Manager | ||||
Allergan Capital S.à r.l. | ||||
DATE: May 11, 2020 | By: | /s/ Maurice Mulders | ||
Name: Maurice Mulders | ||||
Title: Class A Manager | ||||
DATE: May 11, 2020 | By: | /s/ Cesar Acosta | ||
Name: Cesar Acosta | ||||
Title: Class B Manager | ||||
Allergan Finance, LLC | ||||
DATE: May 11, 2020 | By: | /s/ Robert A. Michael | ||
Name: Robert A. Michael | ||||
Title: President | ||||
Warner Chilcott Limited | ||||
DATE: May 11, 2020 | By: | /s/ Patricia Haran | ||
Name: Patricia Haran | ||||
Title: Director |
Annex A
| Name of Entity | Principal executive office | Telephone number | |||
1. | Allergan Funding SCS | 2, Rue Joseph Hackin Grand Duchy of Luxembourg L-1746 Luxembourg | +352 42 7171 3254 | |||
2. | Allergan Capital S.à r.l. | 6 rue Jean Monnet Grand Duchy of Luxembourg L-2180 Luxembourg | +352 2668 3233 | |||
3. | Allergan Finance, LLC | 5 Giralda Madison, New Jersey 07940 | 862 261 7000 | |||
4. | Warner Chilcott Limited | Ocorian Services (Bermuda) Limited Victoria Place, 5th Floor 31 Victoria Street Hamilton HM 10, Bermuda | 353 1 897 2025 |